KVK Tech And Argentum Pharmaceuticals Announce Partnership To Commercialize Pharmaceutical Products Made In The U.S.A.

NEW YORK, Feb. 1, 2016 /PRNewswire/ — Argentum has entered into a nonexclusive collaboration agreement with KVK Tech to launch and commercialize pharmaceutical products.  KVK is a recognized leader in the development and manufacture of high-quality, FDA-approved medicines, and possesses operational expertise in pharmaceutical manufacturing, packaging, sales, distribution, research & development, and customer service. KVK’s expertise runs the gamut and includes solid oral, powder, liquid, and proprietary dosage technologies.  KVK is in the process of expanding its capabilities into aseptic products as well with a 225,000 sq./ft. sterile injectable being qualified this year.  KVK takes pride in its ability to advance medical care and offer low-cost, high-quality alternatives in response to today’s healthcare challenges.  KVK is one of the few manufacturers of generic pharmaceuticals who handles all manufacturing, packaging, and distribution in the United States.

To learn more about KVK, please go to www.kvktech.com


All KVK Tech products are made in the USA in strictest accordance with FDA, DEA, and DEP guidelines

About Argentum Pharmaceuticals
Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors, Argentum intends to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.